Weight Loss Medication Plus IUD Device for Early-Stage Uterine Cancer

Plain-English translation of NCT07107334 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether semaglutide, liraglutide, or tirzepatide—medications originally developed to help with weight loss and blood sugar control—might help treat early-stage uterine cancer when used together with a special IUD that releases hormones directly into the uterus. The study focuses on people living with obesity who either cannot have surgery or want to keep their ability to have children in the future. Recent research suggests these medications may reduce cancer risk, but doctors want to measure exactly how well they work for treating this specific type of cancer.

Some patients with early-stage uterine cancer cannot or do not want to have a hysterectomy (surgical removal of the uterus), and current treatment options are limited. Early evidence suggests this medication may help shrink or control certain cancers, so researchers want to formally test whether combining it with a hormone-releasing IUD could be an effective, non-surgical treatment option.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with early-stage uterine cancer or a precancerous condition called endometrial intraepithelial neoplasia within the past 4 months
you have a BMI of 30 or higher and either have multiple serious health conditions or want to preserve your ability to have children
your cancer has not spread to other parts of your body or invaded deep into the uterine muscle, as confirmed by imaging
you are in overall health condition that allows you to be treated as an outpatient (ECOG score 0-3)

You likely don't qualify if…

you have more advanced or aggressive types of uterine cancer
your cancer has spread to other organs or parts of your body
you have a history of medullary thyroid cancer, pancreatitis, or multiple endocrine neoplasia syndrome type 2
you are currently pregnant, breastfeeding, or have abnormal cervical cell changes
you have a history of hormone-sensitive cancers such as breast cancer

What participation looks like

You would receive both a hormone-releasing IUD (placed by your doctor) and start taking the medication, which is given as a weekly injection or pill depending on which version is used. The study is small—only 20 people total—and researchers will track how well the treatment works and any side effects you experience. Your doctor will monitor your progress over time to see if the cancer shrinks or goes away.

AI-generated summary from trial data · Jun 25, 2026 · Not medical advice

Weight Loss Medication Plus IUD Device for Early-Stage Uterine Cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)